Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 2—February 2015

Evidence for Elizabethkingia anophelis Transmission from Mother to Infant, Hong Kong

Susanna K.P. Lau1, Alan K.L. Wu1, Jade L.L. Teng1, Herman Tse1, Shirly O.T. Curreem, Stephen K.W. Tsui, Yi Huang, Jonathan H.K. Chen, Rodney A. Lee, Patrick C.Y. Woo, and Kwok-Yung YuenComments to Author 
Author affiliations: The University of Hong Kong, Hong Kong (S.K.P. Lau, J.L.L. Teng, H. Tse, S.O.T. Curreem, Y. Huang, J.H.K. Chen, K.-Y. Yuen, P.C.Y. Woo); State Key Laboratory of Emerging Infectious Diseases, Research Centre of Infection and Immunology, Carol Yu Centre for Infection, Hong Kong (S.K.P. Lau, H. Tse, K.Y. Yuen, P.C.Y. Woo); Pamela Youde Nethersole Eastern Hospital, Hong Kong (A.K.L. Wu, R.A. Lee); School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong (S.K.W. Tsui)

Main Article


Clinical characteristics and results of testing for 3 patients infected with Elizabethkingia anophelis, Hong Kong, 2012*

Characteristics Patient 1 Patient 2† Patient 3
Patient age/sex 21 d/M 33y/F 0 d/F
Fever, PPROM
Apnea at birth
Blood test results
Total leukocytes, × 109 cells/L 16.0 (5.0–19.5) 15.2 (3.7–9.3) 5.1 (10.0–27.0)
Neutrophils, × 109 cells/L 6.8 (2.0–9.5) 12.5 (1.8–6.2) 1.2 (5.0–17.0)
Lymphocytes, × 109 cells/L 6.8 (2.5–11.0) 1.7 (1.0–3.2) 3.4 (3.0–10.0)
Monocytes, × 109 cells/L 2.3 (0.2–1.2) 0.8 (0.2–0.7) 0 (0.5–2.0)
Hemoglobin, g/dL 14.0 (11.0–19.0) 10.7 (11.5–15.4) 16.1 (13.5–19.5)
Platelets, × 109/L 180 (180–460) 241 (160–420) 186 (100–300)
C-reactive protein, mg/L
109 (<8.0)
108 (<5.0)
70.6 (<8.0)
CSF test results
Total leukocytes, × 106 cells/L 1,445 NA 5,850
Polymorphs, % 67 NA 1
Lymphocytes, % 33 NA 99
Protein, g/L 1.33 (0.15–0.45) NA 2.69 (0.15–0.45)
Glucose, mmol/L 2.2 (2.8–4.4) NA 1.5 (2.8–4.4)
CSF/serum glucose, %
Positive culture sites for E. anophelis
Blood, CSF
Placental swab, uterine swab
Blood, CSF
Phenotypic characteristics of isolates
Colony pigment Pale yellow None None
Citrate utilization
Delayed positive
Delayed positive
Antimicrobial drug susceptibilities of isolates
Ampicillin Resistant Resistant Resistant
Pipercillin Susceptible Susceptible Susceptible
Cefoperazone/sulbactam Susceptible Susceptible Susceptible
Cefotaxime Intermediate Resistant Resistant
Ceftazidime Resistant Resistant Resistant
Imipenem Resistant Resistant Resistant
Amikacin Resistant Resistant Resistant
Gentamicin Resistant Resistant Resistant
Kanamycin Resistant Resistant Resistant
Streptomycin Resistant Resistant Resistant
Tobramycin Resistant Resistant Resistant
Ciprofloxacin Susceptible Susceptible Susceptible
Moxifloxacin Susceptible Susceptible Susceptible
Tetracycline Resistant Resistant Resistant
Trimethoprim/sulfamethoxazole Susceptible Susceptible Susceptible
Rifampin Susceptible Susceptible Susceptible
Vancomycin MIC, μg/mL
Antimicrobial drug regimen
Ampicillin + cefotaxime; vancomycin + piperacillin + rifampin
Penicillin G; cefuroxime + metronidazole; ciprofloxacin
Ampicillin + cefotaxime; vancomycin + pipercillin/tazobactam + rifampin
Complications None None Respiratory distress, intraventricular hemorrhage

*Reference ranges are shown in parentheses. PPROM, prolonged premature rupture of membranes; CSF, cerebrospinal fluid.
†Mother of patient 3.

Main Article

1These authors contributed equally to this article.

Page created: January 20, 2015
Page updated: January 20, 2015
Page reviewed: January 20, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.